Carlsmed, Inc. Research and Development Expense
Carlsmed, Inc. (CARL) reported Research and Development Expense of $6.04 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- Carlsmed, Inc. research and development expense for the quarter ending 2026-06-30 was $6.04M, a 45.19% increase year-over-year.
- Carlsmed, Inc. research and development expense for the quarter ending 2026-03-31 was $5.18M, a 64.38% increase year-over-year.
- Carlsmed, Inc. research and development expense for the quarter ending 2025-12-31 was $5.26M, a 74.59% increase year-over-year.
- Carlsmed, Inc. research and development expense for the quarter ending 2025-09-30 was $4.45M, a 10.16% increase year-over-year.
- Carlsmed, Inc. research and development expense for fiscal 2025 was $17.02M, a 18.98% increase from fiscal 2024.
- Carlsmed, Inc. research and development expense for fiscal 2024 was $14.30M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.04M 10-Q · filed 2026-08-05 | $11.22M 10-Q · filed 2026-08-05 | $16.48M derived: sum of 3 quarters · filed 2026-08-05 | $20.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $5.18M 10-Q · filed 2026-05-05 | $10.44M derived: sum of 2 quarters · filed 2026-05-05 | $14.89M derived: sum of 3 quarters · filed 2026-05-05 | $19.05M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $5.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $9.71M derived: sum of 2 quarters · filed 2026-02-25 | $13.87M derived: sum of 3 quarters · filed 2026-08-05 | $17.02M 10-K · filed 2026-02-25 |
| 2025-09-30 | $4.45M 10-Q · filed 2025-11-06 | $8.61M derived: sum of 2 quarters · filed 2026-08-05 | $11.76M 10-Q · filed 2025-11-06 | $14.77M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $4.16M 10-Q · filed 2026-08-05 | $7.31M 10-Q · filed 2026-08-05 | $10.32M derived: sum of 3 quarters · filed 2026-08-05 | $14.36M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $3.15M 10-Q · filed 2026-05-05 | $6.17M derived: sum of 2 quarters · filed 2026-05-05 | $10.20M derived: sum of 3 quarters · filed 2026-05-05 | $14.20M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $3.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $7.05M derived: sum of 2 quarters · filed 2026-02-25 | $11.05M derived: sum of 3 quarters · filed 2026-02-25 | $14.30M 10-K · filed 2026-02-25 |
| 2024-09-30 | $4.04M 10-Q · filed 2025-11-06 | $8.03M derived: sum of 2 quarters · filed 2025-11-06 | $11.29M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $4.00M 10-Q · filed 2025-08-28 | $7.25M 10-Q · filed 2025-08-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| ClearPoint Neuro, Inc. (CLPT) | United States | $0.446B | -15.74 |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| NeuroPace Inc (NPCE) | United States | $0.480B | -28.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |